Aduro gets back on track with CRS-207 af­ter FDA lifts par­tial clin­i­cal hold

Just a month af­ter the FDA forced Aduro to halt en­rolling more pa­tients in stud­ies us­ing its can­cer vac­cine CRS-207, the Berke­ley, CA-based biotech says reg­u­la­tors have lift­ed the par­tial hold, giv­ing it a green light to re­sume pro­ceed­ing on plan.

The par­tial hold was in­sti­tut­ed af­ter a pa­tient test­ed pos­i­tive for Lis­te­ria. CRS-207 us­es reengi­neered Lis­te­ria mono­cy­to­genes — re­mov­ing genes in or­der to dis­arm the bac­te­ria — that ex­press mesothe­lin, spark­ing an im­mune re­sponse to a pro­tein con­cen­trat­ed on can­cer cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.